Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Clinical Study of Allogenic CD19-CAR-NK Cells (JD001) in the Treatment of Refractory or Relapsed(r/r) B-cell Hematologic Malignancies

NCT05739227 is registered in ClinicalTrials.gov with Xuzhou Medical University as lead sponsor.

NCT NCT05739227
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05739227 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Clinical Study of Allogenic CD19-CAR-NK Cells (JD001) in the Treatment of Refractory or Relapsed(r/r) B-cell Hematologic Malignancies
Lead sponsor
Xuzhou Medical University
Phase
Phase 1
Overall status
Unknown status
Start date
March 1, 2023
Completion date
May 31, 2025
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, b-cell lymphoma, chronic lymphocytic leukemia